Active	Status	Sponsor type	Region	Phase	Filter
6 Active 12 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
gusacitinib (ASN002) / Sanofi
NCT06238531: A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus	Withdrawn	1	1	US	Gusacitinib	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Systemic Lupus Erythematosus	01/25	01/25
ERAS-007 / Erasca
HERKULES-1, NCT04866134: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors	Active, not recruiting	1/2	200	US	ERAS-007, ERAS-601	Erasca, Inc.	Advanced or Metastatic Solid Tumors	05/25	11/25
HERKULES-3, NCT05039177: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies	Active, not recruiting	1/2	102	US	ERAS-007, Encorafenib, Braftovi, Cetuximab, Erbitux, Palbociclib, Ibrance	Erasca, Inc.	Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma	08/25	12/25
HERKULES-2, NCT04959981: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC	Completed	1b	24	US	ERAS-007, ERAS-601, Osimertinib, Tagrisso, Sotorasib, Lumakras	Erasca, Inc.	Advanced Non-squamous Non-small-cell Lung Cancer	04/23	04/23
ASN004 / Kirilys
ASN004, NCT04410224: Study of in Patients With Advanced Solid Tumors	Completed	1	19	US	ASN004	Kirilys Therapeutics Inc.	Solid Tumor	05/24	05/24
ASN008 / Formation Bio
NCT05870865: A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis	Completed	2	144	US	ASN008, ASN008 Matching Vehicle	TrialSpark	Dermatitis, Atopic, Pruritus	11/23	12/23
ASN009 / Asana BioSci
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
gusacitinib (ASN002) / Sanofi
NCT06238531: A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus	Withdrawn	1	1	US	Gusacitinib	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Systemic Lupus Erythematosus	01/25	01/25
ERAS-007 / Erasca
HERKULES-1, NCT04866134: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors	Active, not recruiting	1/2	200	US	ERAS-007, ERAS-601	Erasca, Inc.	Advanced or Metastatic Solid Tumors	05/25	11/25
HERKULES-3, NCT05039177: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies	Active, not recruiting	1/2	102	US	ERAS-007, Encorafenib, Braftovi, Cetuximab, Erbitux, Palbociclib, Ibrance	Erasca, Inc.	Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma	08/25	12/25
HERKULES-2, NCT04959981: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC	Completed	1b	24	US	ERAS-007, ERAS-601, Osimertinib, Tagrisso, Sotorasib, Lumakras	Erasca, Inc.	Advanced Non-squamous Non-small-cell Lung Cancer	04/23	04/23
ASN004 / Kirilys
ASN004, NCT04410224: Study of in Patients With Advanced Solid Tumors	Completed	1	19	US	ASN004	Kirilys Therapeutics Inc.	Solid Tumor	05/24	05/24
ASN008 / Formation Bio
NCT05870865: A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis	Completed	2	144	US	ASN008, ASN008 Matching Vehicle	TrialSpark	Dermatitis, Atopic, Pruritus	11/23	12/23
ASN009 / Asana BioSci
No trials found